ProCE Banner Activity

Identification and Management of Tardive Dyskinesia 2022

Slideset Download

This presentation on the identification and management of tardive dyskinesia 2022 reviews the relative prevalence of TD in patients with schizophrenia, mood spectrum disorders, and anxiety disorders; and the effective use of VMAT2 inhibitors without discontinuing other essential psychiatric treatments such as antipsychotics and antidepressants.

Released: May 11, 2022

Expiration: May 10, 2023

No longer available for credit.

Share

Faculty

Christoph U. Correll

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany

Robert O. Cotes

Robert O. Cotes, MD, DFAPA

Professor and Distinguished Physician
Director, Clinical & Research Program for Psychosis at Grady Health System
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Jonathan M. Meyer

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This program is supported by educational grants from:

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany

Christoph U. Correll, MD: researcher: Janssen, Teva; consultant/advisor/speaker: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnista, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, Intra-Cellular Therapies, Jamjoom, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-Prophase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, Viatris; individually publicly traded stocks/stock options: Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax, Quantic.

Robert O. Cotes, MD, DFAPA

Professor and Distinguished Physician
Director, Clinical & Research Program for Psychosis at Grady Health System
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Robert O. Cotes, MD, DFAPA: consultant/advisor/speaker: Saladax; researcher: Alkermes, Karuna, Otsuka, Roche.

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Jonathan Meyer, MD: consultant/advisor/speaker: Alkermes, AbbVie, Axsome, Bioexcel, Cervel, ITCI, Karuna, Neurocrine, Otsuka, Relmada, Sunovion, Teva.